research Triple Hormonal Blockade (ADT3): A Patient’s Perspective
Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.
Search
for
Sort by
Research
960-990 / 1000+ results research SUN-144 Initiating Estradiol Hormone Therapy in a Transgender Woman With Multifocal Idiopathic Localization-Related Epilepsy
The patient was satisfied with hormone therapy, and her epilepsy remained stable.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research New Methods of Endocrine Management of Prostatic Cancer
New hormonal therapies can help treat advanced prostate cancer but may cause testicular issues.
research ODP342 Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel
Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
research Gender-Affirming Hormonal Treatment in Transgender People Assigned Female at Birth (AFAB)
research Unusual Anti-Angiogenic Effect of Combined Hormonal Blockade
research Androgen Therapy for Postmenopausal Women; What is New?
research A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
Adding dutasteride to therapy may improve treatment for advanced salivary duct cancer.
research Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer
Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.
research [A patient with advanced recurrent breast cancer who firmly resisted hair loss and was then treated by combination therapy with high-dose toremifene and capecitabine].
The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
research Miscellaneous Topics in Disorders of Endocrine Glands
New diabetes tech and therapies improve care for endocrine disorders.
research Cardiovascular Toxicities of Androgen Deprivation Therapy
ADT for prostate cancer may harm the heart, but GnRH antagonists might be safer.
research Hyperandrogenism Due to a Testosterone-Secreting Sertoli-Leydig Cell Tumor Associated With a Dehydroepiandrosterone Sulfate-Secreting Adrenal Adenoma in a Postmenopausal Woman: Case Presentation and Review of Literature
research ES01.01 Chemotherapy is Strictly Additive to Immunotherapy
Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
research Endocrine intervention for transsexuals
Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
Aromatase inhibitors can cause various adverse reactions, so monitoring is crucial.
research Reporting on Adverse Clinical Events
Monitoring for adverse effects in clinical treatments is crucial.
research Onychomatricoma with classic features: Case report and review of the literature
Hair loss is a common side effect of hormone treatments for cancer.
research TRAPPED IN THE HYPOGLYCEMIA LOOP
Early advanced therapies are crucial for better survival in aggressive insulinoma cases.
research Postmenopausal Hyperandrogenism in a Patient With an Adrenal Adenoma: How Should We Approach It?
Removing both ovaries treated the woman's excess male hormone symptoms.
research Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
research 0478 Outcomes of oral dutasteride and oral minoxidil for treating endocrine therapy-induced alopecia from breast cancer treatment: A case series
research The Effects of Estradiol, Androgens and the Selective Estrogen Modulators: Ospemifene, Raloxifene and Tamoxifen on Explant Cultures of Human Breast Tissue
Including androgens in hormone therapy may lower breast cancer risk.
research Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society* Clinical Practice Guideline
A multidisciplinary approach is crucial for safe and effective hormone treatment in gender-dysphoric individuals, with specific guidelines for adolescents and adults.
research Feasibility and tolerability of eribulin-based chemotherapy versus other chemotherapy regimens for patients with metastatic triple-negative breast cancer: a single-centre retrospective study
Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
research Hormonal Therapies for Individuals with Intersex Conditions
research Endometrioid adenofibroma arising in an endometriotic cyst
A woman's pelvic pain and bleeding led to finding and successfully treating a rare benign tumor in her reproductive system.